Some insurance plans do cover Zepbound for sleep apnea, but coverage almost always requires prior authorization and the right documentation from your provider. If your plan denies the request, that denial is worth appealing, especially since Zepbound is the only GLP-1 medication with FDA approval specifically for obstructive sleep apnea.

The coverage landscape is shifting fast. CVS Caremark dropped Zepbound from its formulary entirely in mid-2025. Multiple class-action lawsuits have been filed challenging these denials. And Medicare now has a specific pathway for Zepbound coverage when prescribed for obstructive sleep apnea (OSA), with a government agreement expected to cap the copay cost at roughly $50/month starting in 2026.

Whether you're trying to figure out if your plan will cover Zepbound before you fill the prescription at your pharmacy, or you've already been denied and need to know what to do next, this guide walks through coverage requirements by plan type, the most common denial reasons, and exactly how to build an appeal that addresses each one.

Does Insurance Cover Zepbound for Sleep Apnea?

Sometimes, yes, but it's usually not automatic.

Coverage generally depends on whether Zepbound is on your plan's formulary, whether you meet your plan's prior authorization requirements, and whether the correct documentation is submitted with the initial request.

Here's why the OSA indication matters so much: Zepbound (tirzepatide) is a GIP/GLP-1 polypeptide receptor agonist and the only GLP-1 medicine FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. That means even if your plan limits coverage of GLP-1s for weight loss, you may still have a path to get Zepbound covered for sleep apnea. This distinction is the foundation of most successful appeals.

What Insurers Typically Require for Coverage

This varies by plan, but the most common things insurance wants to see are below. Call your insurer or visit your member website for a full list of coverage criteria. You can see example coverage criteria from CVS Caremark here.

The CVS Caremark Situation

CVS Caremark removed Zepbound from most formularies effective July 1, 2025, after striking a rebate deal with Wegovy's manufacturer Novo Nordisk. Patients have been directed to switch to Wegovy instead.

For OSA patients, this creates a particularly strong basis for a formulary exception: Wegovy is not FDA-approved for sleep apnea. Zepbound is the only GLP-1 with that indication, so there is no formulary alternative with the same FDA-approved use.

As plans renew for 2026, many patients are receiving similar notifications that Zepbound will not be covered in the new year. 

Multiple ERISA class-action lawsuits have been filed challenging CVS Caremark's denials. 

Medicare Coverage for Zepbound and Sleep Apnea

Medicare Part D may cover Zepbound when prescribed specifically for moderate-to-severe OSA in adults with obesity. This is because Medicare does not cover Zepbound for weight loss alone (federal law excludes anti-obesity medications from Part D unless they have another FDA-approved indication). The December 2024 OSA approval created the coverage pathway that didn't exist before.

CMS proposed expanding Part D to include anti-obesity medications for 2026, but the government decided against it, which means the OSA indication remains the only Medicare pathway for Zepbound.

Key details for Medicare plans:

• Coverage depends on whether your specific Part D plan has added Zepbound for OSA to its formulary. Check using the Medicare.gov Plan Finder or call the number on your card.
• Starting as early as April 2026, a government agreement with Eli Lilly is expected to cap the Medicare copay at approximately $50/month.
• The 2026 annual out-of-pocket costs for Part D is $2,100.
• Medicare Advantage plans (Part C) vary; some have added Zepbound for OSA, others haven't.
• Prior authorization is almost always required.
• Lilly savings cards are not available to government-insured patients (Medicare, Medicaid, Tricare).

If your Part D plan denies coverage, Medicare has its own escalation path: redetermination within 120 days, then QIC reconsideration, then ALJ hearing.

Common Denial Reasons and What to Do About Each One

When it comes to Zepbound for sleep apnea, all of the common denial reasons can be challenged. It's about identifying the right steps to take. Look for language like these in your denial letter under "why your request was denied."

Need help figuring out which reason applies to you and what strategy to use? Use Claimable's guided appeals tool to make it easy.

Prior Authorization Incomplete / Missing Documentation

What it looks like: "Insufficient information," "missing documentation," "clinical records not provided."

What to do: Contact your prescriber's office to find out exactly what was submitted. Compare it against your plan's requirements, then resubmit with a complete packet: sleep study, BMI documentation, diagnosis notes, and treatment plan.

"Not Medically Necessary"

What it looks like: "Does not meet criteria," "not medically necessary."

What to do: Get a copy of your plan's coverage criteria and compare it against your records point by point. File an appeal that directly addresses each criterion, and include a letter of medical necessity from your healthcare provider. If your insurer's criteria don't align with FDA labeling or clinical guidelines, flag that in the appeal.

Not on Formulary

What it looks like: "Not covered," "non-formulary," "preferred alternatives required."

What to do: Appeal and request a formulary exception. Since Zepbound is the only GLP-1 approved for sleep apnea, your exception request has a strong foundation. If the plan is suggesting Wegovy or another GLP-1, those drugs are not FDA-approved for OSA. Clearly state why the suggested alternatives are not appropriate for your diagnosis.

Plan Exclusion / "Weight Loss Only"

What it looks like: "Plan excludes weight-loss medications," "not a covered benefit."

What to do: This is a mis-categorization issue. Zepbound prescribed for OSA is a treatment for a sleep disorder, not a weight-loss prescription. Confirm with your provider that the PA was submitted under ICD-10 code G47.33 (OSA), not obesity. If the coding was correct and the denial still cites a weight-loss exclusion, appeal and clearly distinguish between the two indications.

Step Therapy / Alternative Required

What it looks like: "Must try X first," "step edit."

What to do: If you've already tried alternatives (CPAP, other medications, lifestyle interventions) and they didn't adequately manage your OSA, document those attempts in your appeal. Note that no other GLP-1 is FDA-approved for OSA. Also, 37+ states have step therapy protection laws that may limit your insurer's ability to enforce these requirements.

How to Appeal a Zepbound Sleep Apnea Denial

Most people will be able to reverse a Zepbound denial for sleep apnea when they appeal with the right argument, documentation, and clinical backing. Here's the high-level process.

Your appeal should mirror the denial reason. Quote the denial reason directly, respond with the specific evidence that addresses it, and attach supporting documents with the relevant sections highlighted. Key documents include your denial letter, sleep study report, OSA diagnosis/severity, BMI documentation, provider notes, and (recommended) a letter of medical necessity from your prescribing provider. 

Important deadline: Most commercial plans give you 180 days from the denial date to submit an internal appeal. Don't miss it.

If your first appeal is denied, you can request a second-level internal appeal. After exhausting internal appeals, most plans are required by law to offer access to external review through an independent organization. Your final denial letter should include instructions on how to request it.

Read our full guide to appealing a Zepbound denial for a detailed, step-by-step walkthrough of the appeals process.

How to Get Ahead of a Denial Before It Happens

If your doctor is considering prescribing Zepbound for sleep apnea, you can get ahead of coverage issues from the start.

What to ask your insurer (call the number on your insurance card):

• Is Zepbound covered for obstructive sleep apnea under my specific plan?
• Is it on formulary? If not, what's the exception process?
• What are the prior authorization criteria, and where is the PA form?
• Where should the PA be submitted (portal/fax)?
• What are typical timelines, and what qualifies for an expedited review?

What to confirm with your provider before the PA is submitted:

• Sleep study report and AHI documentation are attached
• Current BMI/weight documentation is included
• Diagnosis is coded under OSA (G47.33), not obesity
• Clinical rationale ties directly to the plan's stated criteria
• Submission goes to the correct portal or fax number

Ongoing Legal Challenges to Zepbound OSA Denials

Several lawsuits are now challenging insurers' categorical denials of Zepbound for sleep apnea. A class-action suit filed in September 2025 alleges CVS Caremark and CareFirst BlueCross BlueShield wrongfully denied coverage in violation of ERISA. A separate suit in New York challenges CVS Caremark's blanket formulary removal. And a third targets Elevance (Anthem) for denying OSA coverage while covering other GLP-1s for different conditions.

These cases are still in progress, but they signal that many denials may not be consistent with plan terms or federal law. Learn more about the legal landscape here.

How Claimable Helps

Navigating insurance appeals is time-consuming and confusing, especially when you're dealing with a condition that affects your sleep and daily functioning. Claimable's appeals tool helps you:

• Identify the most likely reason behind your denial
• Build a customized appeal letter backed by clinical evidence, policy analysis, and relevant legal protections
• Automatically mail and fax your appeal to the right place
• Escalate to the next level if your first appeal is denied

Start your Zepbound sleep apnea appeal with Claimable →

FAQs

Does insurance cover Zepbound for sleep apnea? Some plans do, but coverage typically requires prior authorization. Your provider will need to submit documentation including your sleep study, OSA diagnosis, and BMI. If your plan denies coverage, you have the right to appeal.

What do I do if insurance denies Zepbound for sleep apnea? Get your denial letter and identify the specific reason. Common reasons include missing documentation, "not medically necessary," formulary exclusion, benefit exclusion, or step therapy requirements. File an appeal that directly addresses the stated denial reason with supporting evidence.

Does Medicare cover Zepbound for sleep apnea? Medicare Part D may cover Zepbound when prescribed for moderate-to-severe OSA in adults with obesity. Medicare does not cover it for weight loss alone. A government agreement is expected to cap the Medicare copay at approximately $50/month starting as early as April 2026.

Does CVS Caremark cover Zepbound? As of July 2025, CVS Caremark removed Zepbound from its standard formulary. However, since Zepbound is the only GLP-1 FDA-approved for OSA, you may have strong grounds for a formulary exception.

Can I appeal a plan exclusion denial for Zepbound for sleep apnea? In many cases, yes. Most benefit exclusions apply to weight-loss medications. Since Zepbound is FDA-approved for OSA, a prescription for sleep apnea should not fall under a weight-loss exclusion. Appeal and clearly distinguish between the OSA and weight-loss indications.

What is a formulary exception? A formulary exception is a request for coverage of a medication that isn't on your plan's list of covered drugs. For Zepbound and OSA, the exception argument is particularly strong since no other GLP-1 has FDA approval for sleep apnea.

How long do I have to file an appeal? Most commercial plans give you 180 days. Medicare patients have 120 days. Check your denial letter for exact deadlines.

What clinical evidence supports Zepbound for sleep apnea? The SURMOUNT-OSA trials showed Zepbound reduced breathing disruptions by 55-63% over 52 weeks. Up to 51.5% of participants no longer met OSA criteria after one year.